Save time and get answers to complex questions with AI chat
Adefovir dipivoxil discount cardIs liver function monitoring necessary with lipitorEnhertu loss of exclusivity patent expirationOzempic jordan price 2026Nicardipine brand names
See the DrugPatentWatch profile for Stiolto
Stiolto Respimat® (umeclidinium bromide + vilanterol) 2.5 µg / 2.5 µg inhalation, 4 g cartridge (approx.)
Note: It’s not a rescue inhaler. Use it only as prescribed for regular, long‑term control.
Tip: Use a spacer only if you have difficulty coordinating inhalation with actuation; the Respimat is designed for direct inhalation, so a spacer isn’t typically needed.
Adjustments: CYP2D6 poor metabolizers: may have higher vilanterol exposure; monitor for bronchospasm or tremor. Severe renal/hepatic impairment: not formally studied; use with caution.
Adjustments:
Serious but rare: bronchospasm, paradoxical bronchoconstriction, chest pain, heart failure exacerbation.
General rule: If starting a new drug that may affect β‑agonist activity, monitor for tachycardia, tremor, or palpitations.
Stiolto Respimat® (2.5 µg / 2.5 µg) is a once‑daily inhaled combination of a LAMA and a LABA used for long‑term bronchodilation in COPD and asthma. Use it as prescribed, keep the cartridge dry and below 30 °C, and monitor for side effects, especially in patients with cardiovascular disease or on interacting medications. If you have any doubts about dosing, interactions, or side effects, always consult your healthcare provider.
Other Questions About Stiolto :